Abstracts tagged "longitudinal studies"

Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 2654 • 2014 ACR/ARHP Annual Meeting
Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study
Yang Gao¹, Yi Lo¹, Jacky Wan², Esther YY Lau² and Mo Yin Mok¹, ¹Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Psychology, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Cognitive impairment is commonly reported in patients with systemic lupus erythematosus (SLE) and its associations with neuropsychiatric involvement (NPSLE) and psychiatric factors have been…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…
Abstract Number: 2398 • 2014 ACR/ARHP Annual Meeting
Continued Participation in a 10-Year Tight Control Treat-to-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing Their BeSt?
I.M. Markusse¹, L. Dirven², T.H.E. Molenaar³, N. Riyazi⁴, P.B.J. de Sonnaville⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: To identify risk factors for premature study termination and patients’ motives for adherence to a long term follow-up clinical trial in rheumatoid arthritis (RA).…
Abstract Number: 2248 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis
Anne Lübbeke¹, Matthieu Zingg², Daniel Fritschy¹, Pierre Hoffmeyer¹ and Hermes Miozzari², ¹Orthopaedic Surgery, Geneva University Hospitals, Geneva, Switzerland, ²Orthopaedics, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose Studies evaluating patient-reported long term outcomes (>10 years) after primary TKA are lacking. Moreover, variability in patient satisfaction after TKA has been reported for…
Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting
Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study
Joëlle van den Hoek^1,2, Hendriek C. Boshuizen³, Leo D. Roorda⁴, Gerard J. Tijhuis⁵, Mike T. Nurmohamed⁵, Trudi van den Bos² and Joost Dekker^6,7, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data. We explored variations in…
Abstract Number: 1271 • 2013 ACR/ARHP Annual Meeting
Longitudinal Disease Trajectory Of Juvenile Dermatomyositis
Lily Siok Hoon Lim^1,2, Eleanor Pullenayegum³, Dafna D. Gladman⁴, Earl D. Silverman⁵ and Brian M. Feldman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: 1) To determine the longitudinal disease activity trajectory of an inception cohort of Juvenile Dermatomyositis (JDM) patients, 2) To identify predictor(s) for longitudinal disease…
Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Glenn Haugeberg¹, Torhild Garen², Hege Sommerseth³, Anne Prøven³ and Knut Helgetveit³, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Rheumatology, Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Natalie McCormick¹, Carlo A. Marra², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…
Abstract Number: 901 • 2013 ACR/ARHP Annual Meeting
Smokers and Overweight Persons Are At Increased Risk Of New Onset Of Severe Foot Pain and Persistent Severe Foot Pain In a Population Study
Alyssa B. Dufour¹, Hylton B. Menz², Arunima Awale³, Thomas J. Hagedorn³, Virginia A. Casey³, Patricia P. Katz⁴ and Marian T. Hannan⁵, ¹Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ²Lower Extremity and Gait Studies Program, La Trobe University, Bundoora, Victoria 3086, Australia, ³Institute for Aging Research, Hebrew SeniorLife, Boston, MA, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Few studies have evaluated risk factors for patterns of foot pain in the general population, let alone over time. An understanding of the possible…
Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting
Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Jadwiga Bienkowska³, Andrea Dearth⁴, Norm Allaire⁵ and Ann Ranger⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…
Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting
Cardiac Involvement In Granulomatosis With Polyangiitis
Lucy McGeoch¹, Simon Carette², David Cuthberston³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L Koening⁶, Carol A. Langford⁷, Paul A. Monach⁸, Larry W. Moreland⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹², Carol McAlear¹³, Peter A Merkel¹⁴, Christian Pagnoux² and The Vcrc¹⁵, ¹Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Biostatistics, University of South Florida, Tampa, FL, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Boston University, Boston, MA, ⁹Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].